IMMUNIC, INC. 8-K

What Happened
Immunic, Inc. (IMUX) announced on an 8‑K filed May 19, 2026 that its board appointed Michael W. Bonney as Chair of the Board, effective May 16, 2026. Mr. Bonney, age 67, brings extensive biotech leadership experience (former CEO of Cubist Pharmaceuticals; board/board chair roles at Alnylam, Autolus, Dunad, Santa Ana Bio and others). In connection with his appointment the board size was increased from nine to ten members and Simona Skerjanec will step down as Interim Chairperson and continue as a board member.

Key Details

• Appointment effective: May 16, 2026; 8‑K filed May 19, 2026.
• Equity award: options to purchase 100,000 shares granted effective May 16, 2026, vesting monthly over three years; exercise price = Nasdaq closing price on May 15, 2026. Award is subject to shareholder approval to increase shares available under the 2019 Omnibus Equity Incentive Plan.
• Compensation: Mr. Bonney will receive cash director compensation per the company’s non‑employee director policy and a customary indemnity agreement.
• Governance: Board increased from nine to ten members; no familial or related‑party transactions disclosed requiring Item 404 disclosure.

Why It Matters
A new, experienced board chair can influence corporate governance and strategic oversight—relevant to investors watching management direction and board stability. The option grant could be dilutive if shareholders approve the plan amendment. The filing is a routine governance disclosure (Item 5.02) and was accompanied by a press release (Exhibit 99.1).